Global Human Insulin Drugs and Delivery Devices Market Size study, by Drug Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), by Device Type (Insulin Pens, Insuli

Global Human Insulin Drugs and Delivery Devices Market Size study, by Drug Type (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins), by Device Type (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors) and Regional Forecasts 2022-2028

Global Human Insulin Drugs and Delivery Devices Market is valued at approximately USD 40.3 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3% over the forecast period 2022-2028. Protein hormone insulin helps people whose systems are unable to manufacture enough insulin control high blood sugar levels. By enhancing glucose uptake in fatty tissues and muscles, insulin reduces the blood glucose level. This can be infused in buttocks, belly, backs of the arms, or legs. Additionally, insulin not only aids in the management of diabetes but also in the treatment of its immediate consequences, including diabetic ketoacidosis and hyperosmolar hyperglycemia. The market growth is driven by key factors such as growth in the number of diabetic patients and rising market demand for HI Analogs. According to a Commonwealth Fund study, Americans with diabetes who lack insurance are more likely to use older, less expensive (and less effective) insulin medications than those who have Medicaid or private insurance. 60% to 80% of people without insurance pay the entire list price for insulin, compared to 9% of privately insured patients and 3% of Medicaid recipients. Moreover, expected patent expiry of key HI Drugs propels the market opportunities across the globe. However, stringent regulatory requirements for product approval impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the global Human Insulin Drugs and Delivery Devices Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is leading the overall market share owing to high cases and increasing amount of diabetic patients. However, Asia Pacific is expected to be the fastest growing region due to changing lifestyles of people and unhealthy dietary habits.

Major market players included in this report are:
Novo Nordisk A/S
Insulet
Eli Lilly
Exir
Biocon
Becton Dickinson
Medtronic
Ypsomed
Julphar
Sanofi Aventis

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Application offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Type:
Basal or Long-acting Insulins
Bolus or Fast-acting Insulins
Traditional Human Insulins
Combination Insulins
Biosimilar Insulins

By Device Type:
Insulin Pens
Insulin Pumps
Insulin Syringes
Jet Injectors

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Human Insulin Drugs and Delivery Devices Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

Companies Mentioned

Novo Nordisk A/S
Insulet
Eli Lilly
Exir
Biocon
Becton Dickinson
Medtronic
Ypsomed
Julphar
Sanofi Aventis

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.